within Pharmacolibrary.Drugs.ATC.A;

model A07DA53
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 13.333333333333334,
    adminDuration  = 600,
    adminMass      = 0.004,
    adminCount     = 1,
    Vd             = 0.06,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00045,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Loperamide, in combination with other agents, is an antidiarrheal medication used to manage symptoms of acute or chronic diarrhea. It acts as a peripherally acting Î¼-opioid receptor agonist, reducing intestinal motility and prolonging transit time. Loperamide combinations are commonly used for symptomatic relief and are still approved and in use today globally.</p><h4>Pharmacokinetics</h4><p>No specific pharmacokinetic parameters for loperamide in combination products (ATC A07DA53) found in the literature for healthy adults or population subgroups.</p><h4>References</h4><ol><li>Qian-Meng Lin, Ni-Hong Pang, Ying-Hui Li, Huan-le Huang, Xiao-Dan Zhang, Guo-Xin Hu, Zeng-Shou Wang,Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS.,Chemico-biological interactions,2019<a href='https://pubmed.ncbi.nlm.nih.gov/31299239/'>https://pubmed.ncbi.nlm.nih.gov/31299239/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A07DA53;
